The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Compound

oral semaglutide

Tablet formulation using an absorption enhancer; PIONEER and OASIS programmes.

15 topics 4 solved Synonyms: pioneer-formulation Group: Compound

Related in this group: semaglutide · tirzepatide · retatrutide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · survodutide · mazdutide · amylin analogues

15 topics

TopicParticipantsRepliesViewsActivity
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021)…
CFMASD 2 17k 6h
The SOUL trial and oral semaglutide cardiovascular outcomes
Posting this under the heading it deserves: The SOUL trial and oral semaglutide cardiovascular outcomes Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it…
YMNSMH 2 7.1k 9h
About the Oral incretins category
Oral semaglutide, orforglipron and the absorption problem. PIONEER and OASIS data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
SLJMBMEMRV 4 6.2k 20d
Why oral semaglutide needs an absorption enhancer at all — one year on
Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited…
SCSOOFJREF+11 15 17k 24d
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset
Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…
BFAFMNCLAI+27 31 17k 25d
Oral semaglutide bioavailability and its variability between people
Posting this under the heading it deserves: Oral semaglutide bioavailability and its variability between people Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in…
SHNKITAKAD+44 48 574 3mo
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes
The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…
TWBTAMDRM+100 104 4.2k 5mo
Why oral semaglutide needs an absorption enhancer at all
Why oral semaglutide needs an absorption enhancer at all I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of…
LSHSHBMSAK+59 65 61k 7mo
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SURPASS-4 ( Lancet , 2021)…
CCMDBWGRAZ+130 135 11k 7mo
Oral versus injectable exposure: comparing apples to a different fruit
Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-4 ( JAMA ,…
JMMBCBJNNM+19 23 332 8mo
Food effects on oral incretin absorption: what is documented
On the subject in the title: Food effects on oral incretin absorption: what is documented Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
RMRVAP 2 4.4k 12mo
Revisiting: Food effects on oral incretin absorption: what is documented
Revisiting: Food effects on oral incretin absorption: what is documented — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read it before…
CCIGTDAJEF+6 10 51k 13mo
SNAC and the mechanism of oral peptide absorption — the long version
SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…
RMMATPBB+32 36 6.8k 16mo
SNAC and the mechanism of oral peptide absorption
On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…
PNJPTKGOF+13 17 14k 17mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold?
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session…
CAMMMLRRM+23 27 4.8k 22mo